MYCN and neuroblastoma: Many genetic features of NB, such as amplification of the MYCN proto-oncogene (20–30% of patients), chromosomal aberrations including 1p loss (~30%), 11q loss (~40%), and 17q gain (~50%), and tumor cell ploidy, have been identified, revealing their potential as powerful predictors of response to therapy and outcomes [2].